Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Mutations of the VHL tumour suppressor gene in renal carcinoma
The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.
Comprehensive Characterization of Cancer Driver Genes and Mutations
The Molecular Taxonomy of Primary Prostate Cancer
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival.
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
The present study shows that mutations in FH are associated with HLRCC in North America, and expands the histologic spectrum of renal tumors and FH mutations associated withHLRCC.
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling
- M. Baba, Seung-Beom Hong, B. Zbar
- BiologyProceedings of the National Academy of Sciences
- 17 October 2006
The data suggest that FLCN, mutated in Birt–Hogg–Dubé syndrome, and its interacting partner FNIP1 may be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways.
BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reports
BHDS is characterised by a spectrum of mutations, and clinical heterogeneity both among and within families, and the first germline missense mutation in BHD c.1978A>G (K508R) is reported.
The genetic basis of kidney cancer: a metabolic disease
Mutations in each of these kidney cancer genes result in dysregulation of metabolic pathways involved in oxygen, iron, energy or nutrient sensing, suggesting that kidney cancer is a disease of cell metabolism.